TECHNETIUM TC 99M SESTAMIBI
TECHNETIUM TC 99M SESTAMIBI is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: TECHNETIUM TC 99M SESTAMIBI; Generic name: TECHNETIUM TC 99M SESTAMIBI; Drug class: Radioactive Diagnostic Agent [EPC].
| Brand name | TECHNETIUM TC 99M SESTAMIBI |
|---|---|
| Generic name | TECHNETIUM TC 99M SESTAMIBI |
| Drug class | Radioactive Diagnostic Agent [EPC] |
| Manufacturer | Jubilant Draximage (USA) Inc. |
| Used for | 1 INDICATIONS AND USAGE Myocardial Imaging: Kit for the preparation of Technetium Tc 99m Sestamibi Injection is a myocardial perfusion agent that is indicated for detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects), in evaluating myocardial function and developing information for use in patient management decisions. Technetium Tc 99m Sestamibi evaluation of myocardial ischemia can be accomplished with rest and cardiovascular stress techniques (e.g., exercise or pharmacologic stress in accordance with the pharmacologic stress agents labeling). It is usually not possible to determine the age of a myocardial infarction |
| Dosage | 2 DOSAGE AND ADMINISTRATION For Myocardial Imaging: The suggested dose range for I.V. administration of Technetium Tc 99m Sestamibi in a single dose to be employed in the average patient (70 kg) is 370 to 1110 MBq (10 to 30 mCi). For Breast Imaging: The recommended dose range for I.V. administration of Technetium Tc 99m Sestamibi is a single dose of 740 to 1110 MBq (20 to 30 mCi). For Myocardial Imaging: The suggested dose range for I.V. administration of Technetium Tc 99m Sestamibi in a single |
| Warnings | 5.1 Warnings In studying patients in whom cardiac disease is known or suspected, care should be taken to assure continuous monitoring and treatment in accordance with safe, accepted clinical procedure. Infrequently, death has occurred 4 to 24 hours after Tc 99m Sestamibi use and is usually associated with exercise stress testing [ see General Precautions ( 5.2 ) ]. Pharmacologic induction of cardiovascular stress may be associated with serious adverse events such as myocardial infarction, arrhyt |
| Active ingredient(s) | TECHNETIUM TC-99M SESTAMIBI |
| Route | INTRAVENOUS |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=07c893fc-cfba-1d98-0232-6448463afb87 |